Cargando…
Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt
INTRODUCTION: Although cetuximab has been widely used in the treatment of colon cancer, a large number of patients eventually develop drug resistance. Therefore, it is essential to clarify the mechanism of drug resistance. METHODS: In this study, we combined in silico analysis and a single guide RNA...
Autores principales: | Cai, Ping, Xie, Yangyang, Dong, Mingjun, Zhu, Qiaoqiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744183/ https://www.ncbi.nlm.nih.gov/pubmed/33376716 http://dx.doi.org/10.1155/2020/2046248 |
Ejemplares similares
-
Structural insights reveal the specific recognition of meiRNA by the Mei2 protein
por: Shen, Siyuan, et al.
Publicado: (2022) -
Meis homeobox 2 (MEIS2) inhibits the proliferation and promotes apoptosis of thyroid cancer cell and through the NF-κB signaling pathway
por: Wen, Xiaohui, et al.
Publicado: (2021) -
Mei : per flauto solo (1962)
por: Fukushima, Kazuo
Publicado: (1966) -
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
por: Song, Na, et al.
Publicado: (2014) -
LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways
por: Yuan, Heng-heng, et al.
Publicado: (2022)